journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/29139314/cost-utility-analysis-of-life-long-prophylaxis-with-recombinant-factor-viii-fc-vs-recombinant-factor-viii-for-the-management-of-severe-haemophilia-a-in-sweden
#1
Nathaniel Henry, Jelena Jovanović, Max Schlueter, Persefoni Kritikou, Koo Wilson, Karl-Johan Myrén
AIMS: Prophylaxis with recombinant factor VIII (rFVIII) is the standard of care for severe haemophilia A in Sweden. The need for frequent injections with existing rFVIII products may, however, result in poor adherence to prophylaxis leading to increased bleeding and long-term joint damage. Recombinant FVIIIFc (rFVIIIFc) is an extended half-life fusion protein which can offer prolonged protection and reduced dosing frequency. The objective of this study was to evaluate the cost-utility of prophylaxis with rFVIIIFc in severe haemophilia A from the perspective of the Swedish health system...
November 15, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29139303/effects-of-chinese-urban-public-hospitals-reform-on-revenue-and-compensation-after-removing-drug-markups-case-of-nanjing
#2
Wenxi Tang, Jing Xie, Yijuan Lu, Qizhi Liu, Daniel Malone, Aixia Ma
AIMS: The State Council of China requires that all urban public hospitals must eliminate drug markups by September 2017, and that hospital drugs must be sold at the purchase price. Nanjing-the first city to implement the reform-is studied to evaluate the effects of the comprehensive reform on drug prices in public hospitals and to explore differential compensation plans. METHODS: Sixteen hospitals were selected and financial data were collected over the 48-month period before the reform and for 12 months after the reform...
November 15, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29069948/the-economic-burden-of-kidney-disorders-in-korea
#3
Ju Hee Kim, Seung Hee Ho, Hyun-Jin Kim, Sol Lee
AIMS: To estimate the economic burden of kidney disorders in Korea. MATERIALS AND METHODS: The economic burden of kidney disorders was estimated using a prevalence-based approach. Related kidney diseases in patients with kidney disorders (RPWKD) were defined using codes from the tenth International Classification of Disease (E70-E90, F30-F48, F60-F69, F90-F99, K65-K67, N00-N08, N17-N19, and N30-N39). All diseases in patients with kidney disorders (APWKD) were defined as kidney disorders that involved all disease codes...
November 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29065737/comparison-of-complication-and-conversion-rates-between-robotic-assisted-and-laparoscopic-rectal-resection-for-rectal-cancer-which-patients-and-providers-could-benefit-most-from-robotic-assisted-surgery
#4
Stacey J Ackerman, Shoshana Daniel, Rebecca Baik, Emelline Liu, Shilpa Mehendale, Scott Tackett, Minia Hellan
AIMS: To compare (1) complication and (2) conversion rates to open surgery (OS) from laparoscopic surgery (LS) and robotic-assisted surgery (RA) for rectal cancer patients who underwent rectal resection. (3) To identify patient, physician, and hospital predictors of conversion. MATERIALS AND METHODS: A US-based database study was conducted utilizing the 2012-2014 Premier Healthcare Data, including rectal cancer patients ≥18 with rectal resection. ICD-9-CM diagnosis and procedural codes were utilized to identify surgical approaches, conversions to OS, and surgical complications...
November 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29064320/the-hospital-acquired-conditions-hac-reduction-program-using-cranberry-treatment-to-reduce-catheter-associated-urinary-tract-infections-and-avoid-medicare-payment-reduction-penalties
#5
T L Saitone, R J Sexton, A Sexton Ward
OBJECTIVE: The Affordable Care Act (ACA) established the Hospital-Acquired Condition (HAC) Reduction Program. The Centers for Medicare and Medicaid Services (CMS) established a total HAC scoring methodology to rank hospitals based upon their HAC performance. Hospitals that rank in the lowest quartile based on their HAC score are subject to a 1% reduction in their total Medicare reimbursements. In FY 2017, 769 hospitals incurred payment reductions totaling $430 million. This study analyzes how improvements in the rate of catheter-associated urinary tract infections (CAUTI), based on the implementation of a cranberry-treatment regimen, impact hospitals' HAC scores and likelihood of avoiding the Medicare-reimbursement penalty...
November 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29125368/societal-burden-of-cluster-headache-in-the-united-states-a-descriptive-economic-analysis
#6
Janet H Ford, Damion Nero, Gilwan Kim, Bong Chul Chu, Robert Fowler, Jonna Ahl, James M Martinez
AIM: To estimate direct and indirect costs in patients with a diagnosis of cluster headache in the US. METHODS: Adult patients (18 - 64 years of age) enrolled in the Marketscan Commercial and Medicare Databases with ≥ 2 non-diagnostic outpatient (≥ 30 days apart between the two outpatient claims) or ≥ 1 inpatient diagnoses of cluster headache (ICD-9-CM code 339.00, 339.01, or 339.02) between January 1, 2009 and June 30, 2014, were included in the analyses...
November 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29125033/medical-costs-in-patients-with-heart-failure-after-acute-heart-failure-events-one-year-follow-up-study
#7
Eugene Kim, Hye-Young Kwon, Sang Hong Baek, Haeyoung Lee, Byung-Su Yoo, Seok-Min Kang, Youngkeun Ahn, Bongmin Yang
AIMS: This study investigated annual medical costs using real-world data focusing on acute heart failure. METHODS: The data were retrospectively collected from 6 tertiary hospitals in South Korea. Overall, about 330 patients who were hospitalized for acute heart failure between January 2011 and July 2012 were selected. We collected data on their follow-up medical visits for one year, including medical costs incurred toward treatment. Those who died within the observational period or who had no records of follow-up visits were excluded...
November 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29124993/increasing-economic-burden-caused-by-nephro-geriatric-patients
#8
Mariusz Niemczyk
No abstract text is available yet for this article.
November 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29105528/cost-effectiveness-analysis-of-tissue-plasminogen-activator-in-acute-ischemic-stroke-in-iran
#9
Asrin Amiri, Reza Goudarzi, Mohammadreza Amiresmaili, Farhad Iranmanesh
AIMS: Tissue plasminogen activator (tPA) is used to treat acute ischemic stroke up to 4.5 hours after symptom onset. Its cost-effectiveness in developing countries is not specified yet. This study aimed to study cost-effectiveness of tPA in Iran. METHODS: This is a cost-effectiveness analysis from the perspective of the third party payer to compare IV tPA with no tPA of ischemic stroke. A Markov model with a lifetime horizon was used to analyze the costs and outcomes...
November 5, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29096598/cost-effectiveness-analysis-of-sealing-hemostat-patches-vs-standard-of-care-in-cardiac-surgery
#10
Shelly Ikeme, Luca Weltert, Kevin M Lewis, Gerhard Bothma, Daniela Cianciulli, Nicole Pay, Josh Epstein, Erik Kuntze
BACKGROUND: A recent randomized controlled trial showed that patients undergoing ascending aorta surgery treated with HEMOPATCH to control bleeding had a significantly better hemostasis success rate than with dry or wet gauze compression or similar standard of care (SOC). OBJECTIVE: To compare the cost effectiveness using two different agents for hemostasis (HEMOPATCH versus dry or wet gauze compression or similar SOC) in cardiac surgery from the European hospital perspective...
November 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29039712/the-management-of-refractory-carcinoid-syndrome-challenges-and-opportunities-ahead
#11
Mauro Cives, Eleonora Pellè, Franco Silvestris
No abstract text is available yet for this article.
November 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29034792/medical-resource-utilization-and-costs-for-total-hip-arthroplasty-benchmarking-an-anterior-approach-technique-in-the-medicare-population
#12
Atul F Kamath, Abhishek S Chitnis, Chantal Holy, Jason Lerner, Brian Curtin, Steve Lochow, Charles DeCook, Joel M Matta
AIMS: The anterior approach (AA) for total hip arthroplasty (THA) is associated with more rapid recovery when compared to traditional approaches. The purpose of this study was to benchmark healthcare resource utilization and costs for patients with THA via AA relative to matched patients. MATERIALS AND METHODS: This study queried Medicare claims data (2012-2014) to identify patients who received THA via an AA from experienced surgeons, and matched these patients to a control cohort (all THA approaches)...
November 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28994329/the-value-of-self-medication-summary-of-existing-evidence
#13
Joshua Noone, Christopher M Blanchette
AIM: The aim of this review was to identify the international evidence that is currently available on the economic value of self-care through responsible self-medication, in terms of the measures related to access to treatment, time, and productivity. METHODS: A targeted literature search was conducted for 1990-2016, including data gathered from members of the World Self-Medication Industry and searches on PubMed, EBSCOHost, and Google Scholar. Specific searches of individual drug classes known to be switched to non-prescription status in this period were also conducted...
November 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29022427/confirming-the-timing-of-phase-based-costing-in-oncology-studies-a-case-example-in-advanced-melanoma
#14
Michael Atkins, Anna D Coutinho, Sasikiran Nunna, Komal Gupte-Singh, Michael Eaddy
AIMS: The utilization of healthcare services and costs among patients with cancer is often estimated by the phase of care: initial, interim, or terminal. Although their durations are often set arbitrarily, we sought to establish data-driven phases of care using joinpoint regression in an advanced melanoma population as a case example. METHODS: A retrospective claims database study was conducted to assess the costs of advanced melanoma from distant metastasis diagnosis to death during January 2010-September 2014...
October 30, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28975861/-clinically-nuanced-medicaid-cost-sharing
#15
Elizabeth Q Cliff, A Mark Fendrick
No abstract text is available yet for this article.
October 21, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29047304/real-world-comparison-of-all-cause-hospitalizations-hospitalizations-due-to-stroke-and-major-bleeding-and-costs-for-nonvalvular-atrial-fibrillation-patients-prescribed-oral-anticoagulants-in-a-us-health-plan
#16
Alpesh Amin, Allison Keshishian, Lien Vo, Qisu Zhang, Oluwaseyi Dina, Chad Patel, Kevin Odell, Jeffrey Trocio
AIMS: Compare the risk of all-cause hospitalization and hospitalizations due to stroke/systemic embolism (SE) and major bleeding as well as associated health care costs for nonvalvular atrial fibrillation (NVAF) patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. MATERIALS AND METHODS: NVAF patients initiating apixaban, dabigatran, rivaroxaban, or warfarin were selected from the OptumInsight Research Database from 01JAN2013-30SEP2015. Propensity score matching (PSM) was performed between apixaban and each oral anticoagulant...
October 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29041833/healthcare-costs-in-patients-with-advanced-non-small-cell-lung-cancer-and-disease-progression-during-targeted-therapy-a-real-world-observational-study
#17
Karen E Skinner, Ancilla W Fernandes, Mark S Walker, Melissa Pavilack, Ari VanderWalde
AIMS: To assess healthcare costs during treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A retrospective analysis of medical records of US community oncology practices was conducted. Eligible patients had advanced NSCLC (stage IIIB/IV) diagnosed between January 1, 2008 and January 1, 2015, initiated treatment with erlotinib or afatinib (first-line or second-line), and had disease progression...
October 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28959910/a-systematic-review-of-pharmacoeconomic-guidelines
#18
Ye Zhao, Hai-Ming Feng, Ji Qu, Xiu Luo, Wen-Juan Ma, Jin-Hui Tian
OBJECTIVE: To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological development of PE guidelines. MATERIALS AND METHODS: The authors performed a search for PE guidelines using PubMed, the Cochrane library database, and the websites of the International Society for Pharmacoeconomics and Outcomes Research...
October 15, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29027497/comparative-evaluation-of-treatment-patterns-and-healthcare-utilization-of-newly-diagnosed-rheumatoid-arthritis-patients-by-anti-cyclic-citrullinated-peptide-antibody-status
#19
Lois Lamerato, Kylie Matthews, Kwanza Price, Alan Szymialis, Michael Eaddy, Augustina Ogbonnaya, Huai-Che Shih, Harris Ahmad
BACKGROUND: Anti-cyclic citrullinated peptide (CCP) antibody positivity is an established diagnostic factor for severe disease activity and joint damage and a prognostic factor for aggressive disease in rheumatoid arthritis (RA). OBJECTIVE: To compare RA-related treatment, healthcare utilization, and joint erosion between anti-CCP-positive and anti-CCP-negative RA patients. METHODS: Newly diagnosed RA patients were identified from the Henry Ford Health System database between 1/1/2009 and 12/31/2014; the date of the first RA diagnosis within the study period was the index date...
October 13, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28945173/insulin-degludec-versus-insulin-glargine-u100-for-patients-with-type-1-or-type-2-diabetes-in-the-us-a-budget-impact-analysis-with-rebate-tables
#20
Wendy S Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
BACKGROUND AND AIMS: Drug rebates are almost universally negotiated privately between the manufacturer and the payer in the US. The aim of the present study was to illustrate the use of a "rebate table" to improve the transparency and utility of published budget impact analyses in the US by modeling ranges of hypothetical rebates for two comparators. Worked examples were conducted to illustrate the budgetary implications of using insulin degludec (IDeg) relative to insulin glargine (IGlar) U100 in patients with type 1 or 2 diabetes...
October 12, 2017: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"